Content

Assistive Product
Aphasie-App für Patienten und Patientinnen

Product Type:

Training software

There is an image available for this product:
Aphasie-App für Patienten und Patientinnen

Areas of Application:

- Speech therapy
- for speech disorders
- for aphasic people

Description:

In addition to speech therapy, you can train at home with the neolexon aphasia app. The exercise content in the app is selected together with the therapist in therapy. This means that only the words and sentences that are important in everyday life are practiced.
A lot of help is offered when practicing with the app. For example, a video can be played in which the word is spoken. There is a feedback whether the answer was right or wrong. The therapist accompanies the self-training and can constantly adapt it to the learning progress.
The neolexon aphasia app can also be used without computer knowledge.

Features / Components:

- suitable for tablet (Android and iOS)
- 7,800 words
- 1,200 words
- a free version and paid versions are available for therapists

Note: The aphasia app can only be used in combination with speech therapists who are registered with neolexon and stop self-training. Reimbursement of costs is possible at individual health insurance companies.

Price (without guarantee):

The price is available on request from the manufacturer / distributor.

Further Information

Product Information from the Manufacturer / Distributor:

Further Product Details

REHADAT does not sell any products

Please contact the manufacturer or distributor.

Manufacturer:

neolexon UG
Atelierstr. 29
81671 München
Germany Telephone: 089 24886-4440 Email: info@neolexon.de Homepage: https://neolexon.de

Distributor:

neolexon UG
Atelierstr. 29
81671 München
Germany Telephone: 089 24886-4440 Email: info@neolexon.de Homepage: https://neolexon.de

No data available

Keywords

ISO

Search for similar prodcuts in REHADAT:
Search for similar products in EASTIN throughout Europe:

ICF Items

Reference Number:

Hil133402


Source :

DIAS


Last Update: 28 Apr 2020